What is it about?

cystamine has been successfully conjugated with graphene oxide (GO) as a drug carrier. The current study used the microdilution method to determine the minimum inhibitory concentrations of cystamine-conjugated GO against four types of pathogenic bacteria. Minimum inhibitory concentrations values were 1 μg/mL against Escherichia coli and Salmonella typhimurium, 6 μg/mL against Enterococcus faecalis, and 4 μg/mL against Bacillus subtilis.

Featured Image

Why is it important?

Our protocol produced a cystamine-conjugated GO with low cytotoxicity, but strong reactive oxygen species effects and high antibacterial activity. This nanohybrid may be useful in the treatment of dermatological disorders. Moreover, this class of nanohybrid may have other biomedical applications due to their low cytotoxicity and high antibacterial activity.


There is extensive ongoing research designed to expand our knowledge on the roles of oxidative stress and its mediators in human diseases such as atherosclerosis, cardiovascular diseases, diabetes, cancer, and neurodegenerative disorders. In the current study, we found an increased production of ROS in the functionalization of cystamine-conjugated GO, and demonstrated that this material exhibits good antibacterial activity against two different Gram-positive, and two different Gram-negative bacteria. In order to elucidate the mechanism of ROS production, additional studies are needed. Nevertheless, these results suggest that cystamine-conjugated GO will have an important role in the field of biomedicine.

Dr. Sitansu Sekhar Nanda
Myongji University

Read the Original

This page is a summary of: Oxidative stress and antibacterial properties of a graphene oxide-cystamine nanohybrid, International Journal of Nanomedicine, January 2015, Taylor & Francis,
DOI: 10.2147/ijn.s75768.
You can read the full text:




The following have contributed to this page